Home∕News & Press∕Adolor Corporation Announces Positive Results from Phase 2 Program in OIC
Adolor Corporation
Announces Positive Results from Phase 2 Program in OIC
Aug. 10, 2011
“Opioid analgesics have become a cornerstone of multimodal therapy for the management of patients who suffer with chronic non-cancer pain,” said Neil Singla, M.D., lead investigator for the Phase 2 program.